HER2 양성 전이성 유방암 환자에서 trastuzumab-deruxtecan 관련 사회경제적 편익 분석

In the recent DESTINY-Breast03 trial, trastuzumab deruxtecan (T-DXd) has shown significantly prolongedprogression free survival (PFS) compared with trastuzumab emtansine (T-DM1) among human epidermal growth factor2-positive metastatic breast cancer (HER2+ MBC) patients. While there is clear evidence...

Full description

Saved in:
Bibliographic Details
Published inYaghag-hoi-ji Vol. 67; no. 4; pp. 252 - 260
Main Authors 최아형, 고화연, 홍빈, 배지환, 오인선, 박선경, 박연희, 신주영
Format Journal Article
LanguageKorean
Published The Pharmaceutical Society Of Korea 31.08.2023
대한약학회
Subjects
약학
HER2 positive metastatic breast cancer
Trastuzumab-deruxtecan
Socioeconomic benefits
Online AccessGet full text
ISSN0377-9556
2383-9457
DOI10.17480/psk.2023.67.4.252

Cover

Table of Contents:
  • 서 론(Introduction) 방 법(Methods) 결 과(Results) 고 찰(Discussion) 결 론(Conclusion) 감사의 말씀(Acknowledgment) Conflict of Interest References